GH vs. MDLN: Guardant Health vs. Medline Stock Comparison

Company Profile

Guardant Health (GH) and Medline (MDLN) both fall under the Health Care Equipment & Services industry group, but GH is classified in Health Care Providers & Services while MDLN is classified in Health Care Equipment & Supplies.

Guardant Health (GH) has been public since October 4, 2018 with a meaningfully longer listed history, while Medline (MDLN) only listed on December 17, 2025 — long-window metrics on the MDLN side should be interpreted with caution.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Guardant Health (GH) has a non-negative beta of 1.69.

Risk-Adjusted Performance

Risk-Return Positioning

Both GH and MDLN need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Medline (MDLN) earns 4.85% on shareholders’ equity, ranked against its industry; Guardant Health (GH) has no ROE this period.

Guardant Health (GH) reports a negative net margin of -37.93%, usually indicating a net loss over the period. Meanwhile Medline (MDLN) reports 1.85%, ranking against industry peers normally.

Guardant Health (GH) reports a negative operating margin of -37.06%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Medline (MDLN) reports 5.22%, ranking against industry peers normally.

Profitability Metrics

Growth

Only one side can be read here: Guardant Health (GH) reports revenue growth of 32.88%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Only one side can be read here: Medline (MDLN) reports EPS growth of 117.38%, ranked against its industry; Guardant Health (GH) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Guardant Health (GH) at 3.60 keeps current ratio within its industry’s typical mid-range, while Medline (MDLN) at 4.04 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.

Only one side’s leverage can be read here: Medline (MDLN) carries debt-to-equity ratio of 0.65 against its industry range, while Guardant Health (GH) reports no figure this period.

Financial Strength Metrics

Dividends

Neither Guardant Health (GH) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Guardant Health (GH) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Medline (MDLN) trades at 90.09 times trailing earnings, ranked against its peers, while Guardant Health (GH) has no P/E ratio this period.

Medline (MDLN) at 1.70 prices around its industry’s typical P/S ratio, while Guardant Health (GH) at 15.96 clears its benchmark range — GH looks notably rich on sales.

Guardant Health (GH) reports a negative P/B ratio of -73.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Medline (MDLN) reports 2.95, ranking against industry peers normally.

Valuation Metrics